Verona Pharma
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 79
- Market Cap
- -
- Website
- http://www.veronapharma.com
- Introduction
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
- Conditions
- COPD
- Interventions
- Drug: PlaceboDrug: RPL554 SuspensionDrug: Tiotropium/olodaterol (Respimat)
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 79
- Registration Number
- NCT03673670
- Locations
- 🇺🇸
Clinical Site Partners, LLC, Winter Park, Florida, United States
🇺🇸Allied Biomedical Research Holdings, d/b/a Vitalink Research, Greenville, South Carolina, United States
🇬🇧Respiratory Clinical Trials LTD,, London, United Kingdom
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
- Conditions
- COPD
- Interventions
- Drug: PlaceboDrug: RPL554 suspension
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 405
- Registration Number
- NCT03443414
- Locations
- 🇧🇬
Clinic for pneumonology, Pleven, Bulgaria
🇧🇬SHATPPD-Ruse EOOD, Ruse, Bulgaria
🇧🇬Fifth MHAT - Sofia EAD, Sofia, Bulgaria
The Effects of RPL554 in Addition to Tiotropium in COPD Patients
- Conditions
- Chronic Obstructive Pulmonary Disease Moderate
- Interventions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 30
- Registration Number
- NCT03028142
A Study of RPL554 in Patients With Cystic Fibrosis
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 10
- Registration Number
- NCT02919995
- Locations
- 🇬🇧
Papworth Hospital, Cambridge, United Kingdom
The Effects of RPL554 on Top of Standard COPD Reliever Medications
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: RPL554 matched placebo
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 36
- Registration Number
- NCT02542254
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 29
- Registration Number
- NCT02427165
- Locations
- 🇸🇪
Skane University Hospital, Lund, Sweden
🇬🇧Celerion, Belfast, United Kingdom
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects
- Conditions
- Inflammatory Disorder of the Respiratory TractChronic Obstructive Pulmonary Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 112
- Registration Number
- NCT02307162
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom